Investigating therapeutic response to netarsudil in glaucoma subjects with the ARHGEF12 risk variant
Joan M. O’Brien
IntroductionARHGEF12 variants, which regulate the RhoA/ROCK pathway, are associated with primary open-angle glaucoma (POAG) in individuals of African ancestry and may influence response to Rho-kinase inhibitors such as netarsudil.MethodsWe analyzed 1,844 African ancestry subjects with POAG, comparing baseline demographic and ocular phenotypes across ARHGEF12 genotype groups (non-carriers, heterozygous carriers, and homozygous carriers). Netarsudil response was evaluated in a subset of 66 subject